News

Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea ...
The agreement values Mural Oncology at up to $36.2 million, with shareholders set to receive a base cash payment and ...
The collaboration will leverage Boehringer Ingelheim’s manufacturing expertise to accelerate AnGes’ HGF gene therapy toward ...
In a joint statement, 1 the White House and the EU announced the details of what is being called a framework for an agreement ...
Darzalex Faspro's supply and availability remain unaffected, and no new clinical studies were requested by the FDA.
As HHS Secretary, Kennedy cut nearly $500 million in funding for mRNA vaccine research. While he says that the decision was made after looking at the science, health experts have heavily criticized ...